About Scienture

A Novel Opioid Overdose Emergency Treatment

At 10 mg, REZENOPY is the highest FDA-approved dose per nasal spray for naloxone HCI in the U.S. market, designed for emergency treatment of known or suspected opioid overdoses, including those involving potent synthetic opioids. It is intended for immediate, single-dose administration to reverse respiratory or central nervous system depression.1

Key Details About REZENOPY:

  • Highest Dose: It provides the highest dose per nasal spray for naloxone (10 mg) currently approved by the FDA.
  • Administration: It is a single-use, needle-free spray, administered into one nostril.
  • Effectiveness: It is designed to act fast against strong opioids, with additional doses (in the other nostril) possible every 2-3 minutes if no response is seen.
  • Manufacturer & Distribution: Developed in collaboration with Kindeva Drug Delivery, with Scienture LLC handling US commercialization.

Read the News Release >

REZENOPY is the highest FDA-approved dose per nasal spray for naloxone HCI in the U.S. market.

Scienture logo.

Prioritizing Patients. Improving Outcomes.

Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients, physicians, and caregivers by offering novel specialty products to satisfy unmet patient needs. The assets in development at Scienture span across therapeutic areas and indications and are intended to cater to different market segments and channels.

Scienture Holdings, Inc. (NASDAQ: SCNX) is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians, and caregivers by offering novel specialty products to satisfy unmet patient needs.

References

  1. REZENOPY™ (naloxone HCl) nasal spray 10 mg [prescribing information]. Commack, NY; Scienture, LLC 2025.